Past Featured Speakers

  • Francis LeeDirector, Tumor Pharmacology and Experimental Therapeutics Bristol-Myers Squibb

  • Hui GaoResearch Investigator III, Oncology Pharmacology Novartis

  • Deepak SampathSenior Scientist, Translational Oncology, Genentech

  • Corinne ReimerAssociate Director, In Vivo Pharmacology, Oncology iMed Science Unit AstraZeneca

Highlights from Tumor Models Boston 2014

The 3rd Annual Tumor Models Boston recently ran in July 2014 with over 70 pre-clinical oncologists and tumor model developers in attendance to network, interact and find solutions to enable them to make more clinically relevant predictions and improve the translational success of candidates into human clinical trials.

Attendees discovered industry defining information, effective preclinical strategies and expanded their network to achieve effective analysis and interpretation of data derived from tumour models. 

Here's a snapshot of what was covered:

  • Learn how to run large scale preclinical phase II-like studies with tumor models that better represent the patient population
  • Discover how emerging personalized mouse avatars and co-clinical trials will de-risk later stage clinical development
  • Harness patient derived xenograft (PDX) models to optimize biomarker identification, stratify patient populations and improve translational decision making 
  • Explore novel pharmaco-imaging technology with improved resolution to validate and prioritize drug candidates
  • Learn how RNA Seq technology can allow you to make the connection between preclinical models and clinical outcomes
  • Harness in silico modeling and simulation to translate preclinical data into the design of human clinical trials
  • Discover the technological and logistical advances in tumor models that can increase the translatability of your preclinical studies
  • Learn how to overcome the challenge of tumor heterogeneity through accurate biological modeling
  • Discover how to target the tumor microenvironment with models that identify cancer initiation, progression and resistance mechanisms
  • Understand the clinician’s perspective on tumor model data and improve cross-collaboration for more cost-effective drug development

What's next for the Tumor Model Community?

  • We'll be running a Tumour Models London event, 2nd-4th December, so if you missed Boston why not think about joining us in London?
  • We'll be putting together a post event report for Boston so do keep an eye out for that - it will cover all the key takeaways and learnings from the meeting
  • Do continue to interact with us, and your peers, on our Linkedin group - just search Tumour Models 

Don't miss our London event: